Dear Molecular Imaging Insider,
I thought you'd like to know about these two articles we've posted today in your Molecular Imaging Digital Community:
The use of certain PET/CT parameters for diagnosing mediastinal disease in non-small cell lung cancer patients. Italian researchers have questioned the conclusions of a recent Irish study, and we bring you the latest news about the controversy. Click here to find out more.
Tumor heterogeneity plays a vital role in how we understand and treat cancers, but the clinical translation of this has lagged behind advances in research. U.K. researchers explain how emerging techniques are making a difference in this area. To learn more, click here.
Also, we have two further articles from this month's high-level Brussels meeting, "Paving the way to the best sustainable molecular healthcare model in Europe," which was organized by the Association of Imaging Producers & Equipment Suppliers:
Dr. Val Lewington from King's College London expressed her deep concern that although molecular imaging is at the forefront of innovation and opens the way to personalized medicine, the message is still not getting through to key decision-makers. She explains why here.
Dr. Richard Baum, from Bad Berka in Germany, urged national health institutes to do more to encourage clinical and basic scientists to communicate better. Europeans do excellent basic research, but there's a lack of translation, and translational research must "cross the Valley of Death," he said. Click here to read more.
Meanwhile, the U.K. Royal College of Radiologists (RCR) has published updated recommendations for the use of pediatric PET/CT. You can download the 16-page document free of charge from the RCR's website. Get the story here.
This is only a small selection of articles that have appeared over recent weeks in your Molecular Imaging Digital Community. The full list appears below this letter.
